Reckitt’s Core Business Gap Widens as M&A Hopes Outpace Reality

Reckitt shares rose 3.6% on reports that Danone is exploring a bid for its Mead Johnson infant nutrition unit. This move fits a classic pattern: a 'buy the rumor' pop. The market has been here before. When Reckitt first announced its own $16.6 billion acquisition of Mead Johnson back in 2017, the stock popped 5.5% on the news. Now, with a potential sale to a strategic buyer like Danone, the same dynamic is playing out. The rumor itself is priced in as a positive catalyst.

The critical expectation gap, however, is not in the Mead Johnson story. It's in Reckitt's core business. The company's underlying performance has been under pressure. Last quarter, Reckitt lowered its full-year sales growth outlook due to supply issues, a move that disappointed investors. This creates a fragile setup. The stock is being bid up on a speculative M&A story while the fundamentals of its day-to-day operations are being reset lower.

Viewed another way, the 3.6% pop is a small victory for the rumor, but it does nothing to close the widening gap between the market's expectations for Reckitt's core health and hygiene business and the reality of its recent performance. The expectation gap for the core business is widening, while the market is focused on the potential exit for one of its units.

The Strategic Reset: Divestments and Capital Return

Reckitt's strategic pivot is now in motion, but the execution reveals a complex reality. The company has sold a majority stake in its homecare brands to Advent International for up to £3.6 billion, a move that clears a key hurdle in its plan to become a simpler, core-focused health and hygiene company. Yet the deal's structure introduces a significant complication: Reckitt will retain a 30 per cent stake in the portfolio. This retained interest means the company remains exposed to the performance and potential liabilities of those brands, creating a messy, partial exit rather than a clean break.

The capital return plan is the financial engine of this reset. Following the sale, Reckitt intends to return around £1.6 billion to shareholders via a special dividend and a share consolidation. This plan was recently given a strong vote of confidence, with shareholders approving the measures overwhelmingly. The mechanics are designed to be neutral: the special dividend will be paid, and a consolidation of 24 new shares for every 25 old ones will reduce the share count proportionally, aiming to keep the per-share price stable. In theory, this is a credible alternative to a potential sale of the Nutrition business-it offers immediate value to shareholders.

In practice, however, the plan is a fragile one. It hinges on resolving two major overhangs. First, it requires the successful conclusion of costly safety litigation in the US related to its infant nutrition products. Second, it depends on a clean exit for the Mead Johnson unit itself. As analysts noted, the litigation needs to be resolved ahead of a then hoped-for sale of nutrition. The capital return plan, therefore, is a key part of the strategic narrative, but it is not a standalone solution. It is a bridge to be crossed only after the more difficult, and more valuable, divestment of the Nutrition business is settled. For now, the retained stake and the pending legal battles mean the market's focus remains firmly on the next, more complex hurdle.

Valuation and Forward Scenarios: What's Priced In?

The market's current valuation reflects a clear split in expectations. On one side, Jefferies raised its price target to 5,900 GBp, citing confidence in Reckitt's portfolio reshaping. On the other, Deutsche Bank trimmed its target to 5,460 GBp, signaling a more cautious view on execution. This divergence captures the core tension: the market is pricing in a successful strategic reset, but it is deeply skeptical about the path there.

What is priced in is a company in transition. The sale of its homecare brands for up to £3.6 billion and the plan to return capital are the bullish narrative. Yet, the retained 30% stake and the unresolved Abbott litigation create a messy, overhanging risk. The fair value estimate has been trimmed, with analysts now assuming a 0.53% decline in long-term revenue growth. This is a direct reflection of the expectation gap widening in the core business, not just in Mead Johnson.

The Mead Johnson unit itself is the central puzzle. It accounts for 15% of Reckitt's total revenue and has been a persistent drag, marred by write-downs and lawsuits. That makes it a compelling target for a strategic buyer like Danone, which is "discreetly exploring" a buyout. The market is pricing in this potential sale as a positive catalyst, which explains the recent pop. But the unit's poor performance is the very reason a sale is being considered, not a sign of strength.

The key catalyst that will determine if the reset succeeds or fails is the resolution of the Abbott litigation. As analysts have noted, this must happen before a clean exit for the Nutrition business can proceed. Until that overhang is lifted, the capital return plan remains a bridge to nowhere. The stock offers a classic expectation arbitrage: the rumor-driven pop is small, the core business's expectation gap is widening, and the outcome of the litigation will dictate whether the strategic reset is a success story or a forced sale becomes the only path.